Working... Menu

Mechanisms of Improvement With Beta-Blocker Treatment in Heart Failure

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01261065
Recruitment Status : Completed
First Posted : December 16, 2010
Last Update Posted : December 16, 2010
Information provided by:
Michael Debakey Veterans Affairs Medical Center

Brief Summary:
The overall hypothesis of this application is that the improvement in LV ejection performance following treatment with betablockers is due, at least in part, to improvement in intrinsic myocardial contractility.

Condition or disease Intervention/treatment Phase
Heart Failure Cardiomyopathy Drug: carvedilol Phase 4

Detailed Description:
The immediate specific objectives of this application are two-fold: (1) to determine whether the observed improvement in LV ejection performance is due to alterations in intrinsic cardiac myocardial contractility and (2) to determine whether changes in LV contractile reserve following an infusion of intravenous milrinone can be used to predict a salutary response to beta-blockers. The immediate specific objectives of this proposal will be addressed in the following two Specific Aims: In Specific Aim 1, we will determine whether the observed improvement in LV ejection fraction following treatment with beta-blockers is due to changes in intrinsic myocardial contractility, as opposed to changes in LV remodeling (i.e. reduction in LV volume) or changes in LV loading conditions. Changes in LV function will be evaluated using proven indexes, one an ejection phase index: the relation of end-systolic stress (ESS) to the mean velocity of fiber shortening (VCF), considered a relatively load independent measure of contractility. Changes in LV structure will be evaluated using echocardiography. In Specific Aim 2, we will determine whether the salutary response to beta-blockers can be predicted by measuring "contractile reserve", defined as a change in contractility determined by the relation of the mean velocity of fiber shortening (VCF) to end-systolic stress (ESS) in response to intravenous milrinone infusion at the cardiac catheterization lab prior to the institution of beta-blockade. The response to treatment with beta-blockers will be assessed by measurement of LV ejection fraction and LV end-diastolic volume by echocardiography after 6 months of treatment with beta-blockers, and these measurements will be correlated with the respective changes in contractile reserve measurement at baseline.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 55 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Diagnostic
Official Title: Mechanisms of Improvement With Beta-Blocker Treatment in Heart Failure
Study Start Date : December 2001
Actual Primary Completion Date : October 2005
Actual Study Completion Date : October 2005

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Heart Failure

Intervention Details:
  • Drug: carvedilol
    Patients with heart failure and LVEF < 35 % were treated with maximally tolerated dose of carvedilol for a period of six months. Target dose was 25 mg bid or 37.5 mg bid if patient's baseline weight > 80 kg.
    Other Name: coreg

Primary Outcome Measures :
  1. Load independent measure of contractility: Left ventricular velocity of circumferential shortening to left ventricular end systolic stress ratio [ Time Frame: 6 months ]
    Mean velocity of circumferential fiber shortening (VCF) will be derived as = Left Ventricular Fractional shortening / Ejection Time.Left ventricular (LV) end-systolic stress will be calculated as = ([1.35 × P × LV endsysolic diameter]/(4 × LV posterior wall thickness in systole × (1+LV posterior wall thickness in systole /LV endsysolic diameter)))

Secondary Outcome Measures :
  1. Left ventricular end diastolic and end systolic volumes, left ventricular end systolic stress, effective arterial elastance [ Time Frame: 6 months ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Patients 18 years of age or older.
  2. Man or nonpregnant women (only women who are postmenopausal, surgically sterile or practicing an acceptable method of contraception)
  3. Patients with dilated nonischemic cardiomyopathy with LVEF< 35% and NYHA Class III-IVa heart failure
  4. Patients on standard stable medical therapy with Ace inhibitors (or hydralazine and nitrates or Angiotensin II Receptor blockers if Ace-intolerant), diuretics and or digoxin for at least 1 month prior to enrollment in the study.
  5. Heart failure symptoms have to be present for at least 3 months
  6. Written informed consent

Exclusion Criteria:

  1. Ischemic heart disease documented by cardiac catheterization with any coronary obstructive lesion > 50% stenosis, history of myocardial infarction, coronary artery bypass surgery , percutaneous coronary angioplasty or stenting
  2. Uncorrected primary valvular disease, obstructive or restrictive cardiomyopathy.
  3. Systolic blood pressure >170 or <85 mm Hg or diastolic blood pressure >100 mm Hg; heart rate <50 bpm.
  4. Sick sinus syndrome or advanced heart block (unless treated by a pacemaker), symptomatic or sustained ventricular tachycardia not controlled by antiarrhythmic drugs or an implantable defibrillator
  5. Cor pulmonale, obstructive pulmonary disease requiring oral bronchodilator or steroid therapy
  6. Active malignancy, or a systemic or terminal disease that would limit physical function or survival during the trial
  7. Active and known drug or alcohol dependence or any factors that will interfere with the study conduct or interpretation of results.
  8. Clinically important hepatic or renal disease; or any condition other than heart failure that could limit survival
  9. Platelet count <100 000 mm3 or white blood cell count <3000 mm3, INR (international normalized ratio) >1.7
  10. Current treatment with beta-blocker, beta-agonist, verapamil, chronic cyclic or continuous inotropic therapy, or use of an investigational drug within 30 days of entry into the challenge phase
  11. History of drug sensitivity or adverse reactions to beta-blockers
  12. Unwillingness to cooperate or give written informed consent, pregnant or lactating women

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01261065

Layout table for location information
United States, Texas
Michael E. DeBakey Veterans Affairs Medical Center
Houston, Texas, United States, 77030
Sponsors and Collaborators
Michael Debakey Veterans Affairs Medical Center
Layout table for investigator information
Principal Investigator: Biykem Bozkurt, MD Michael E.DeBakey VA Medical Center, Baylor College of Medicine

Layout table for additonal information
Responsible Party: Biykem Bozkurt , MD, Michael E. DeBakey VA Medical Center, Baylor College of Medicine Identifier: NCT01261065     History of Changes
Other Study ID Numbers: VA-CDA
First Posted: December 16, 2010    Key Record Dates
Last Update Posted: December 16, 2010
Last Verified: December 2010

Keywords provided by Michael Debakey Veterans Affairs Medical Center:
beta blockers
heart failure

Additional relevant MeSH terms:
Layout table for MeSH terms
Heart Failure
Heart Diseases
Cardiovascular Diseases
Adrenergic beta-Antagonists
Adrenergic Antagonists
Adrenergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs
Antihypertensive Agents
Protective Agents
Calcium Channel Blockers
Membrane Transport Modulators
Calcium-Regulating Hormones and Agents
Vasodilator Agents
Adrenergic alpha-1 Receptor Antagonists
Adrenergic alpha-Antagonists